Breaking News Instant updates and real-time market news.

FL

Foot Locker

$60.16

-10.295 (-14.61%)

, ADDYY

adidas

$96.66

0.54 (0.56%)

09:51
05/19/17
05/19
09:51
05/19/17
09:51

Foot Locker says sales of Stan Smiths, Superstars 'off their pinnacle'

FL

Foot Locker

$60.16

-10.295 (-14.61%)

ADDYY

adidas

$96.66

0.54 (0.56%)

  • 19

    May

  • 15

    Jun

FL Foot Locker
$60.16

-10.295 (-14.61%)

05/19/17
SBSH
05/19/17
NO CHANGE
Target $92
SBSH
Buy
Foot Locker earnings selloff a buying opportunity, says Citi
Citi analyst Kate McShane views today's post-earnings selloff in shares of Foot Locker as a buying opportunity. The quarter, as previously indicated, was negatively impacted by a slow start to the year and delayed tax refund checks in February, McShane tells investors in a research note. She continues to see market share gains for Foot Locker and keeps a Buy rating on the shares with a $92 price target.
04/20/17
04/20/17
UPGRADE

Buy
Update: Foot Locker upgraded on accelerating trends at Buckingham
As previously reported, Buckingham upgraded Foot Locker to Buy from Neutral and raised its price target to $89 from $77 based on expectations for an acceleration in same-store-sales trends, expanding merchandise margins, and increased share buybacks. The firm believes the major long-term bear thesis on Footlocker that customers move to Nike.com is more muted with other athletic brands gaining share and said the company has a sustainable and defensible concept that resonates with customers.
04/20/17
BUCK
04/20/17
UPGRADE
BUCK
Buy
Foot Locker upgraded to Buy from Neutral at Buckingham
02/27/17
ADAM
02/27/17
NO CHANGE
Target $87
ADAM
Buy
Foot Locker reiterated as a top pick for 2017 at Canaccord
Canaccord analyst Camilo Lyon noted Foot Locker reported solid Q4 results and bucked the trend of a challenging retail environment. Lyon cited the company's ability to drive positive store traffic, its ability to execute with consistency, and its stock buyback program. Lyon maintained his Buy rating and raised his price target to $87 from $83 on Foot Locker shares.
ADDYY adidas
$96.66

0.54 (0.56%)

04/20/17
PIPR
04/20/17
UPGRADE
Target $62
PIPR
Overweight
Genesco upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Erinn Murphy upgraded Genesco (GCO) to Overweight saying the risk/reward is favorable at current share levels. Genesco offers a "compelling way" to play adidas (ADDYY), Murphy tells investors in a research note. She lowered her price target for the shares to $62 from $63.
04/06/17
OPCO
04/06/17
INITIATION
OPCO
Outperform
adidas initiated with an Outperform at Oppenheimer
Oppenheimer analyst Anna Andreeva initiated adidas with an Outperform rating and price target of EUR 205, saying she believes the Retro/Lifestyle trend that the company dominates in is still early on and that its focus on Performance is paying off.
04/05/17
JEFF
04/05/17
NO CHANGE
Target $27
JEFF
Buy
Jefferies sees 'significant upside' in Under Armour, says buy now
Jefferies analyst Randal Konik says his dissection of TickerTags data, which tracks social media mentions through Twitter, shows the social share gains at adidas (ADDYY) in 2016 have peaked and that Under Armour's sponsorship strategy is "lifting brand heat." The data, along with channel checks that show athletic trends are healthy, indicate the Under Armour brand is strong, Konik tells investors in a research note. With a large global growth opportunity, a "severely compressed" market cap and "overly negative" sell-side analysts, now is the time to buy the stock, Konik again argues. He sees "significant upside" in the shares and keeps a Buy rating on Under Armour with a $27 price target. The stock closed yesterday down 34c to $19.31.
04/04/17
04/04/17
DOWNGRADE

Hold
Nike downgraded to Hold on slowing growth at Argus
As previously reported, Argus analyst John Staszak downgraded Nike (NKE) to Hold from Buy as he expects the company's growth to slow over the next 12 months due to competition from Adidas (ADDYY) and Under Armour (UAA).

TODAY'S FREE FLY STORIES

BIIB

Biogen

$338.10

-4.32 (-1.26%)

, ESALY

Eisai

$53.38

-0.25 (-0.47%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Hot Stocks
Biogen, Eisai expand existing collaboration agreement »

Eisai Co., Ltd. (ESALY)…

BIIB

Biogen

$338.10

-4.32 (-1.26%)

ESALY

Eisai

$53.38

-0.25 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

NITE

Nightstar Therapeutics

$19.00

-0.1 (-0.52%)

07:19
10/23/17
10/23
07:19
10/23/17
07:19
Initiation
Nightstar Therapeutics initiated  »

Nightstar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Earnings
Potlatch reports Q3 EPS ex-items 94c, consensus 90c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Hot Stocks
Potlatch raises dividend to 40c per share from 37.5c per share »

Potlatch announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAIC

SAIC

$70.88

1.04 (1.49%)

07:18
10/23/17
10/23
07:18
10/23/17
07:18
Upgrade
SAIC rating change  »

SAIC upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GGB

Gerdau

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Gerdau initiated  »

Gerdau resumed with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Vale initiated  »

Vale resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCCO

Southern Copper

$43.13

-0.16 (-0.37%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Southern Copper initiated  »

Southern Copper resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBR

Fibria Celulose

$16.24

0.45 (2.85%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Initiation
Fibria Celulose initiated  »

Fibria Celulose resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Hot Stocks
Mike Covey to continue to serve as chairman and CEO of combined Potlatch, Deltic »

The leadership team will…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

GOOG

Alphabet

$988.20

3.75 (0.38%)

, GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

07:17
10/23/17
10/23
07:17
10/23/17
07:17
Periodicals
Google plans to share revenues with news publishers, FT reports »

Google is planning to…

GOOG

Alphabet

$988.20

3.75 (0.38%)

GOOGL

Alphabet Class A

$1,005.07

3.23 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

  • 08

    Nov

  • 15

    Nov

  • 29

    Nov

  • 18

    Mar

BIIB

Biogen

$338.10

-4.32 (-1.26%)

07:16
10/23/17
10/23
07:16
10/23/17
07:16
Downgrade
Biogen rating change  »

Biogen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

PCH

Potlatch

$53.00

-0.35 (-0.66%)

, DEL

Deltic Timber

$89.12

0.98 (1.11%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Potlatch, Deltic Timber to combine in all-stock transaction »

Potlatch Corporation…

PCH

Potlatch

$53.00

-0.35 (-0.66%)

DEL

Deltic Timber

$89.12

0.98 (1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 02

    Nov

PSTI

Pluristem

$1.77

-0.035 (-1.94%)

07:15
10/23/17
10/23
07:15
10/23/17
07:15
Hot Stocks
Pluristem receives European patent covering PLX-R18 »

Pluristem Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
10/23/17
10/23
07:15
10/23/17
07:15
General news
FX Update: The dollar traded firmer »

FX Update: The dollar…

HAL

Halliburton

$43.33

-0.09 (-0.21%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Hot Stocks
Halliburton CEO says 'North American business is hitting on all cylinders' »

"We had a strong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GNTX

Gentex

$19.38

-1.28 (-6.20%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Recommendations
Gentex analyst commentary  »

Gentex added to Alpha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WGO

Winnebago

$47.75

1.9 (4.14%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Recommendations
Winnebago analyst commentary  »

Winnebago price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDHL

RedHill Biopharma

$9.25

0.47 (5.35%)

07:14
10/23/17
10/23
07:14
10/23/17
07:14
Hot Stocks
RedHill Biopharma receives notice of allowance for new U.S. patent for RHB-104 »

RedHill Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHE

Benchmark Electronics

$30.50

-0.5 (-1.61%)

07:13
10/23/17
10/23
07:13
10/23/17
07:13
Conference/Events
Benchmark Electronics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 08

    Nov

USAP

Universal Stainless & Alloy

$21.79

1.24 (6.03%)

07:13
10/23/17
10/23
07:13
10/23/17
07:13
Hot Stocks
Universal Stainless & Alloy announces favorable amendment of credit agreement »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

NBIX

Neurocrine

$59.03

0.07 (0.12%)

07:13
10/23/17
10/23
07:13
10/23/17
07:13
Hot Stocks
Neurocrine's Ingrezza granted FDA orphan status as Tourette syndrome treatment »

Neurocrine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

MITK

Mitek Systems

$9.60

0.1 (1.05%)

07:12
10/23/17
10/23
07:12
10/23/17
07:12
Hot Stocks
Mitek Systems enters partnership with Asignio »

Mitek announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$99.12

1.64 (1.68%)

07:12
10/23/17
10/23
07:12
10/23/17
07:12
Hot Stocks
State Street: Outlook for rest of 2017 in line with Q2, improved from January »

Says current outlook for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NVS

Novartis

$85.74

-0.42 (-0.49%)

07:11
10/23/17
10/23
07:11
10/23/17
07:11
Hot Stocks
Novartis monoclonal antibodies granted FDA orphan status for CMV prevention »

Novartis' human IgG1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 17

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.